Progress in the discovery of Polo-like kinase inhibitors

Current Topics in Medicinal Chemistry

Volumn 5, Issue 2, 2005, Pages 181-197

  McInnes, Campbell ^a   Mezna, Mokdad ^a   Fischer, Peter M ^a  

^a CYCLACEL LTD   (United Kingdom)

Author keywords

Docking; Homology model; Inhibitor; Mitosis; Polo like kinase

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ADENOSINE TRIPHOSPHATE; ANTISENSE OLIGONUCLEOTIDE; AURINTRICARBOXYLIC ACID; CYCLIN DEPENDENT KINASE INHIBITOR; DAIDZEIN; DIAMINE DERIVATIVE; FISETIN; FLAVONOID; GALANGIN; INDOLE DERIVATIVE; KAEMPFEROL; LUTEOLIN; MORIN; MYRICETIN; NATURAL PRODUCT; ON 01910; PACLITAXEL; PHENOL DERIVATIVE; PHOSPHOTRANSFERASE INHIBITOR; POLO LIKE KINASE; POLO LIKE KINASE 1; PURVALANOL A; QUERCETIN; SCYTONEMIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; STAUROSPORINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WORTMANNIN;

CELL PROLIFERATION; CYTOKINESIS; DISEASE COURSE; DRUG ACTIVITY; DRUG DESIGN; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MITOSIS; NONHUMAN; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; RNA INTERFERENCE;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN-SERINE-THREONINE KINASES;

EID: 17144393305     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026053507660     Document Type: Review

References (161)

1. Llamazares, S.; Moreira, A.; Tavares, A.; Girdham, C.; Spruce, B. A.; Gonzalez, C.; Karess, R. E.; Glover, D. M.; Sunkel, C. E. Polo encodes a protein kinase homolog required for mitosis in Drosophila. Genes Dev. 1991, 5, 2153-2165.
2. Glover, D. M.; Hagan, I. M.; Tavares, A. A. Polo-like kinases: a team that plays throughout mitosis. Genes Dev. 1998 12, 3777-3787.
3. Nigg, E. A. Mitotic kinases as regulators of cell division and its checkpoints. Nat. Rev. Mol. Cell Biol. 2001, 2, 21-32.
4. Barr, F. A.; Sillje, H. H. W.; Nigg, E. A. Polo-like kinases and the orchestration of cell division. Nat. Rev. Mol. Cell Biol. 2004, 5, 429-441.
5. Hamanaka, R.; Maloid, S.; Smith, M. R.; O'Connell, C. D.; Longo, D. L.; Ferris, D. K. Cloning and characterization of human and murine homologues of the Drosophila polo serine-threonine kinase. Cell Growth Differ. 1994, 5, 249-257.
6. Simmons, D. L.; Neel, B. G.; Stevens, R.; Evett, G.; Erikson, R. L. Identification of an early-growth-response gene encoding a novel putative protein kinase. Mol. Cell. Biol. 1992, 12, 4164-4169.
7. Donohue, P. J.; Alberts, G. F.; Guo, Y.; Winkles, J. A. Identification by targeted differential display of an immediate early gene encoding a putative serine/threonine kinase. J. Biol. Chem. 1995, 270, 10351-10357.
8. Ouyang, B.; Pan, H.; Lu, L.; Li, J.; Stambrook, P.; Li, B.; Dai, W. Human Prk is a conserved protein serine/threonine kinase involved in regulating M phase functions. J. Biol. Chem. 1997, 272 28646-28651.
9. Karn, T.; Holtrich, U.; Wolf, G.; Hock, B.; Strebhardt, K.; Ruebsamen-Waigmann, H. Human SAK related to the PLK/polo family of cell cycle kinases shows high mRNA expression in testis. Oncol. Rep. 1997, 4, 505-510.
10. Fode, C.; Motro, B.; Yousefi, S.; Heffernan, M.; Dennis, J. W. Sak, a murine protein-serine/threonine kinase that is related to the Drosophila polo kinase and involved in cell proliferation. Proc. Natl. Acad. Sci. USA 1994, 91, 6388-6392.
11. Lee, K. S.; Yuan, Y.-L. O.; Kuriyama, R.; Erikson, R. L. Plk is an M-phase-specific protein kinase and interacts with a kinesin-like protein, CHO1/MKLP-1. Mol. Cell. Biol. 1995, 15, 7143-7151.
12. Hamanaka, R.; Smith, M. R.; O'Connor, P. M.; Maloid, S.; Mihalic, K.; Spivak, J. L.; Longo, D. L.; Ferris, D. K. Polo-like kinase is a cell cycle-regulated kinase activated during mitosis. J. Biol. Chem. 1995, 270, 21086-21091.
13. Ferris, D. K.; Maloid, S. C.; Li, C.-C. H. Ubiquitination and proteasome mediated degradation of polo-like kinase. Biochem. Biophys. Res. Commun. 1998, 252, 340-344.
14. Nurse, P. Universal control mechanism regulating onset of M-phase. Nature 1990, 344, 503-508.
15. Roshak, A. K.; Capper, E. A.; Imburgia, C.; Fornwald, J.; Scott, G.; Marshall, L. A. The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase. Cell. Signalling 2000, 12, 405-411.
16. Liu, F.; Stanton, J. J.; Wu, Z.; Piwnica-Worms, H. The human Myt1 kinase preferentially phosphorylates Cdc2 on threonine 14 and localizes to the endoplasmic reticulum and Golgi complex. Mol. Cell. Biol. 1997, 17, 571-583.
17. Parker, L. L.; Atherton-Fessler, S.; Piwnica-Worms, H. The p107weel is a dual-specificity kinase that phosphorylates p34cdc2 on tyrosine 15. Proc. Natl. Acad. Sci. USA 1992, 89, 2917-2921.
18. Gautier, J.; Solomon, M. J.; Booher, R. N.; Bazan, J. F.; Kirschner, M. W. cdc25 is a specific tyrosine phosphatase that directly activates p34cdc2. Cell 1991, 67, 197-211.
19. Sebastian, B.; Kakizuka, A.; Hunter, T. Cdc25M2 activation of cyclin-dependent kinases by dephosphorylation of threonine-14 and tyrosine-15. Proc. Natl. Acad. Sci. USA 1993, 90, 3521-3524.
20. Abrieu, A.; Brassac, T.; Galas, S.; Fisher, D.; Labbe, J.-C.; Doree, M. The Polo-like kinase P1×1 is a component of the MPF amplification loop at the G2/M-phase transition of the cell cycle in Xenopus eggs. J. Cell Sci. 1998, 111, 1751-1757.
21. Toyoshima-Morimoto, F.; Taniguchi, E.; Nishida, E. Plk1 promotes nuclear translocation of human Cdc25C during prophase. EMBO Rep. 2002, 3, 341-348.
22. Bahassi, E. M.; Hennigan, R. F.; Myer, D. L.; Stambrook, P. J. Cdc25C phosphorylation on serine 191 by Plk3 promotes its nuclear translocation. Oncogene 2004, 23, 2658-2663.
23. Hagting, A.; Karlsson, C.; Clute, P.; Jackman, M.; Pines, J. MPF localization is controlled by nuclear export. EMBO J. 1998 17, 4127-4138.
24. Hagting, A.; Jackman, M.; Simpson, K.; Pines, J. Translocation of cyclin B1 to the nucleus at prophase requires a phosphorylation-dependent nuclear import signal. Curr. Biol. 1999, 9, 680-689.
25. Jackman, M.; Lindon, C.; Nigg, E. A.; Pines, J. Active cyclin B1-Cdk1 first appears on centrosomes in prophase. Nat. Cell Biol. 2003, 5, 143-148.
26. Casenghi, M.; Meraldi, P.; Weinhart, U.; Duncan, P. I.; Koerner, R.; Nigg, E. A. Polo-like kinase 1 regulates Nlp, a centrosome protein involved in microtubule nucleation. Dev. Cell 2003, 5, 113-125.
27. Dai, W.; Wang, Q.; Traganos, F. Polo-like kinases and centrosome regulation. Oncogene 2002, 21, 6195-6200.
28. Adams, R. R.; Tavares, A. A. M.; Salzberg, A.; Bellen, H. J.; Glover, D. M. pavarotti encodes a kinesin-like protein required to organize the central spindle and contractile ring for cytokinesis. Genes Dev. 1998, 12, 1483-1494.
29. Zhou, T.; Aumais, J. P.; Liu, X.; Yu-Lee, L.-Y.; Erikson, R. L. A role for Plk1 phosphorylation of NudC in cytokinesis. Dev. Cell 2003, 5, 127-138.
30. Lane, H. A.; Nigg, E. A. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J. Cell. Biol. 1996, 135, 1701-1713.
31. Van Vugt, M. A. T. M.; Bras, A.; Medema, R. H. Polo-like Kinase-1 Controls Recovery from a G2 DNA Damage-Induced Arrest in Mammalian Cells. Mol. Cell 2004, 15, 799-811.
32. Golan, A.; Yudkovsky, Y.; Hershko, A. The cyclin-ubiquitin ligase activity of cyclosome/APC is jointly activated by protein kinases Cdk1-cyclin B and Plk. J. Biol. Chem. 2002, 277, 15552-15557.
33. Weitzer, S.; Uhlmann, F. Chromosome segregation: playing polo in prophase. Dev. Cell 2002, 2, 381-382.
34. Alexandru, G.; Uhlmann, F.; Mechtler, K.; Poupart, M.-A.; Nasmyth, K. Phosphorylation of the cohesin subunit Sccl by Polo/Cdc5 kinase regulates sister chromatid separation in yeast. Cell 2001 105, 459-472.
35. Sumara, I.; Vorlaufer, E.; Stukenberg, P. T.; Kelm, O.; Redemann, N.; Nigg Erich, A.; Peters, J.-M. The dissociation of cohesin from chromosomes in prophase is regulated by Polo-like kinase. Mol. Cell 2002, 9, 515-525.
36. Kraft, C.; Herzog, F.; Gieffers, C.; Mechtler, K.; Hagting, A.; Pines, J.; Peters, J.-M. Mitotic regulation of the human anaphase-promoting complex by phosphorylation. EMBO J. 2003, 22, 6598-6609.
37. Musacchio, A.; Hardwick, K. G. The spindle checkpoint: structural insights into dynamic signalling. Nat. Rev. Mol. Cell Biol. 2002, 3, 731-741.
38. Moshe, Y.; Boulaire, J.; Pagano, M.; Hershko, A. Role of Polo-like kinase in the degradation of early mitotic inhibitor 1, a regulator of the anaphase promoting complex/cyclosome. Proc. Natl. Acad. Sci. USA 2004, 101, 7937-7942.
39. Kotani, S.; Tugendreich, S.; Fujii, M.; Jorgensen, P. M.; Watanabe, N.; Hoog, C.; Hieter, P.; Todokoro, K. PKA and MPF-activated polo-like kinase regulate anaphase-promoting complex activity and mitosis progression. Mol. Cell 1998, 1, 371-380.
40. Feng, Y.; Longo, D. L.; Ferris, D. K. Polo-like kinase interacts with proteasomes and regulates their activity. Cell Growth Differ. 2001, 12, 29-37.
41. Ma, S.; Charron, J.; Erikson, R. L. Role of Plk2 (Snk) in mouse development and cell proliferation. Mol. Cell. Biol. 2003 23, 6936-6943.
42. Bahassi, E. M.; Conn, C. W.; Myer, D. L.; Hennigan, R. F.; McGowan, C. H.; Sanchez, Y.; Stambrook, P. J. Mammalian Polo-like kinase 3 (Plk3) is a multifunctional protein involved in stress response pathways. Oncogene 2002, 21, 6633-6640.
43. Wang, Q.; Xie, S.; Chen, J.; Fukusawa, K.; Naik, U.; Traganos, F.; Darzynkiewicz, Z.; Jhanwar-Uniyal, M.; Dai, W. Cell cycle arrest and apoptosis induced by human polo-like kinase 3 mediated through perturbation of microtubule integrity. Mol. Cell. Biol. 2002, 22, 3450-3459.
44. Conn, C. W.; Hennigan, R. F.; Dai, W.; Sanchez, Y.; Stambrook, P. J. Incomplete cytokinesis and induction of apoptosis by overexpression of the mammalian polo-like kinase, Plk3. Cancer Res. 2000, 60, 6826-6831.
45. Ruan, Q.; Wang, Q.; Xie, S.; Fang, Y.; Darzynkiewicz, Z.; Guan, K.; Jhanwar-Uniyal, M.; Dai, W. Polo-like kinase 3 is Golgi localized and involved in regulating Golgi fragmentation during the cell cycle. Exp. Cell Res. 2004, 294, 51-59.
46. Kauselmann, G.; Weiler, M.; Wulff, P.; Jessberger, S.; Konietzko, U.; Scafidi, J.; Staubli, U.; Bereiter-Hahn, J.; Strebhardt, K.; Kuhl, D. The polo-like protein kinases Fnk and Snk associate with a Ca(2+)- and integrin-binding protein and are regulated dynamically with synaptic plasticity. EMBO J. 1999, 18, 5528-5539.
47. Lee, K. S.; Erikson, R. L. Plk is a functional homolog of Saccharomyces cerevisiae Cdc5, and elevated Plk activity induces multiple septation structures. Mol. Cell. Biol. 1997, 17, 3408-3417.
48. Morgan, D. O. Principles of CDK regulation. Nature 1995, 374, 131-134.
49. Huang, W.; Erikson, R. L. Constitutive activation of Mek1 by mutation of serine phosphorylation sites. Proc. Natl. Acad. Sci. USA 1994, 91, 8960-8963.
50. Jang, Y.-J.; Ma, S.; Terada, Y.; Erikson, R. L. Phosphorylation of Threonine 210 and the Role of Serine 137 in the Regulation of Mammalian Polo-like Kinase. J. Biol. Chem. 2002 277, 44115-44120.
51. Mundt, K. E.; Golsteyn, R. M.; Lane, H. A.; Nigg, E. A. On the regulation and function of human polo-like kinase 1 (PLK1): effects of overexpression on cell cycle progression. Biochem. Biophys. Res. Commun. 1997, 239, 377-385.
52. Qian, Y.-W.; Erikson, E.; Maller, J. L. Purification and cloning of a protein kinase that phosphorylates and activates the polo-like kinase P1×1. Science 1998, 282, 1701-1704.
53. Erikson, E.; Haystead, T. A. J.; Qian, Y.-W.; Maller, J. L. A Feedback Loop in the Polo-like Kinase Activation Pathway. J. Biol. Chem. 2004, 279, 32219-32224.
54. Kuramochi, S.; Moriguchi, T.; Kuida, K.; Endo, J.; Semba, K.; Nishida, E.; Karasuyama, H. LOK is a novel mouse STE20-like protein kinase that is expressed predominantly in lymphocytes. J. Biol. Chem. 1997, 272, 22679-22684.
55. Ellinger-Ziegelbauer, H.; Karasuyama, H.; Yamada, E.; Tsujikawa, K.; Todokoro, K.; Nishida, E. Ste20-like kinase (SLK), a regulatory kinase for polo-like kinase (Plk) during the G2/M transition in somatic cells. Genes to Cells 2000, 5, 491-498.
56. Kelm, O.; Wind, M.; Lehmann Wolf, D.; Nigg Erich, A. Cell Cycle-regulated Phosphorylation of the Xenopus Polo-like Kinase P1×1. J. Biol. Chem. 2002, 277, 25247-25256.
57. Jang, Y.-J.; Lin, C.-Y.; Ma, S.; Erikson, R. L. Functional studies on the role of the C-terminal domain of mammalian polo-like kinase. Proc. Natl. Acad. Sci. USA 2002, 99, 1984-1989.
58. de Carmo Avides, M.; Tavares, A.; Glover, D. M. Polo kinase and Asp are needed to promote the mitotic organizing activity of centrosomes. Nat. Cell Biol. 2001, 3, 421-424.
59. Smith, M. R.; Wilson, M. L.; Hamanaka, R.; Chase, D.; Kung, H.; Longo, D. L.; Ferris, D. K. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem. Biophys. Res. Commun. 1997, 234, 397-405.
60. Wolf, G.; Elez, R.; Doermer, A.; Holtrich, U.; Ackermann, H.; Stolle, H. J.; Altmannsberger, H.-M.; Rübsamen-Waigmann, H.; Strebhardt, K. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997, 14, 543-549.
61. Yuan, J.; Hoerlin, A.; Hock, B.; Stutte, H. J.; Ruebsamen-Waigmann, H.; Strebhardt, K. Polo-like kinase, a novel marker for cellular proliferation. Am. J. Pathol. 1997, 150, 1165-1172.
62. Tokumitsu, Y.; Mori, M.; Tanaka, S.; Akazawa, K.; Nakano, S.; Niho, Y. Prognostic significance of polo-like kinase expression in esophageal carcinoma. Int. J. Oncol. 1999, 15, 687-692.
63. Takahashi, T.; Sano, B.; Nagata, T.; Kato, H.; Sugiyama, Y.; Kunieda, K.; Kimura, M.; Okano, Y.; Saji, S. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci. 2003 94, 148-152.
64. Ito, Y.; Miyoshi, E.; Sasaki, N.; Kakudo, K.; Yoshida, H.; Tomoda, C.; Uruno, T.; Takamura, Y.; Miya, A.; Kobayashi, K.; Matsuzuka, F.; Matsuura, N.; Kuma, K.; Miyauchi, A. Polo-like kinase 1 overexpression is an early event in the progression of papillary carcinoma. Br. J. Cancer 2004, 90, 414-418.
65. Ahmad, N. Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer. FASEB J. 2004, 18, 5-7.
66. Gray, P. J.; Nagle, R.; Hoff, D. D. V.; Bearss, D. J. Identification of the polo-like kinase plk-1 as a therapeutic target in pancreatic cancer. Proc. Amer. Assoc. Cancer Res. 2003, 44 Abs. 4618.
67. Knecht, R.; Oberhauser, C.; Strebhardt, K. PLK (polo-like kinase), a new prognostic marker for oropharyngeal carcinomas. Int. J Cancer 2000, 89, 535-536.
68. Knecht, R.; Elez, R.; Oechler, M.; Solbach, C.; Von Ilberg, C.; Strebhardt, K. Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res. 1999, 59, 2794-2797.
69. Weichert, W.; Schmidt, M.; Gekeler, V.; Denkert, C.; Stephan, C.; Jung, K.; Loening, S.; Dietel, M.; Kristiansen, G. Polo-like kinase I is overexpressed in prostate cancer and linked to higher tumor grades. Prostate 2004, 60, 240-245.
70. Weichert, W.; Denkert, C.; Schmidt, M.; Gekeler, V.; Wolf, G.; Koebel, M.; Dietel, M.; Hauptmann, S. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br. J. Cancer 2004, 90, 815-821.
71. Okada, H.; Mak, T. W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat. Rev. Cancer 2004, 4, 592-603.
72. Castedo, M.; Perfettini, J.-L.; Roumier, T.; Andreau, K.; Medema, R.; Kroemer, G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004, 23, 2825-2837.
73. Cogswell, J. P.; Brown, C. E.; Bisi, J. E.; Neill, S. D. Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function. Cell Growth Differ. 2000, 11, 615-623.
74. Dai, W.; Li, Y.; Ouyang, B.; Pan, H.; Reissmann, P.; Li, J.; Wiest, J.; Stambrook, P.; Gluckman, J. L.; Noffsinger, A.; Bejarano, P. PRK, a cell cycle gene localized to 8p21, is downregulated in head and neck cancer. Genes Chromosomes & Cancer 2000, 27, 332-336.
75. Li, B.; Ouyang, B.; Pan, H.; Reissmann, P. T.; Slamon, D. J.; Arceci, R.; Lu, L.; Dai, W. prk, A cytokine-inducible human protein serine/threonine kinase whose expression appears to be down-regulated in lung carcinomas. J. Biol. Chem. 1996, 271, 19402-19408.
76. Smits, V. A. J.; Klompmaker, R.; Arnaud, L.; Rijksen, G.; Nigg, E. A.; Medema, R. H. Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat. Cell Biol. 2000, 2, 672-676.
77. van Vugt, M. A.; Smits, V. A.; Klompmaker, R.; Medema, R. H. Inhibition of Polo-like Kinase-1 by DNA Damage Occurs in an ATM- or ATR-dependent Fashion. J. Biol. Chem. 2001, 276, 41656-41660.
78. Yuan, J.-H.; Feng, Y.; Fisher, R. H.; Maloid, S.; Longo, D. L.; Ferris, D. K. Polo-Like kinase 1 inactivation following mitotic DNA damaging treatments is independent of ataxia telangiectasia mutated kinase. Mol. Cancer Res. 2004, 2, 417-426.
79. Kawabe, T. G2 checkpoint abrogators as anticancer drugs. Mol. Cancer Ther. 2004, 3, 513-519.
80. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88, 323-331.
81. Ando, K.; Ozaki, T.; Yamamoto, H.; Furuya, K.; Hosoda, M.; Hayashi, S.; Fukuzawa, M.; Nakagawara, A. Polo-like Kinase 1 (Plk1) Inhibits p53 Function by Physical Interaction and Phosphorylation. J. Biol. Chem. 2004, 279, 25549-25561.
82. Ree, A. H.; Bratland, A.; Landsverk, K. S.; Fodstad, O. Ionizing radiation inhibits the PLK cell cycle gene in a G2 checkpoint-dependent manner. Anticancer Res. 2004, 24, 555-562.
83. Lee, M.; Daniels, M. J.; Venkitaraman, A. R. Phosphorylation of BRCA2 by the Polo-like kinase Plk1 is regulated by DNA damage and mitotic progression. Oncogene 2004, 23, 865-872.
84. Spankuch-Schmitt, B.; Wolf, G.; Solbach, C.; Loibl, S.; Knecht, R.; Stegmuller, M.; von Minckwitz, G.; Kaufmann, M.; Strebhardt, K. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene 2002, 21, 3162-3171.
85. Elez, R.; Piiper, A.; Giannini, C. D.; Brendel, M.; Zeuzem, S. Polo-like kinase 1, a new target for antisense tumor therapy. Biochem. Biophys. Res. Commun. 2000, 269, 352-356.
86. Elez, R.; Piiper, A.; Kronenberger, B.; Kock, M.; Brendel, M.; Hermann, E.; Pliquett, U.; Neumann, E.; Zeuzem, S. Tumor regression by combination antisense therapy against Plk1 and Bcl-2. Oncogene 2003, 22, 69-80.
87. Cory, S.; Huang, D. C. S.; Adams, J. M. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003, 22 8590-8607.
88. Schepers, U.; Kolter, T. RNA interference: a new way to analyze protein function. Angew. Chem. Int. Ed. 2001, 40 2437-2439.
89. Dorsett, Y.; Tuschl, T. siRNAS: applications in functional genomics and potential as therapeutics. Nat. Rev. Drug Disc. 2004, 3, 318-329.
90. Liu, X.; Erikson Raymond, L. Activation of Cdc2/cyclin B and inhibition of centrosome amplification in cells depleted of Plk1 by siRNA. Proc. Natl. Acad. Sci. USA 2002, 99, 8672-8676.
91. Spankuch-Schmitt, B.; Bereiter-Hahn, J.; Kaufmann, M.; Strebhardt, K. Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J. Natl. Cancer Inst. 2002, 94, 1863-1877.
92. Liu, X.; Erikson, R. L. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100, 5789-5794.
93. Sui, G.; Soohoo, C.; Affar, E. B.; Gay, F.; Shi, Y.; Forrester, W. C.; Shi, Y. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. USA 2002, 99, 5515-5520.
94. Spaenkuch, B.; Matthess, Y.; Knecht, R.; Zimmer, B.; Kaufmann, M.; Strebhardt, K. Cancer Inhibition in Nude Mice After Systemic Application of U6 Promoter-Driven Short Hairpin RNAs Against PLK1. J. Natl. Cancer Inst. 2004, 96, 862-872.
95. Burns, T. F.; Fei, P.; Scata, K. A.; Dicker, D. T.; El-Deiry, W. S. Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol. Cell. Biol. 2003, 23, 5556-5571.
96. Soutschek, J.; Akinc, A.; Bramlage, B.; Charisse, K.; Constien, R.; Donoghue, M.; Elbashir, S.; Geick, A.; Hadwiger, P.; Harborth, J.; John, M.; Kesavan, V.; Lavine, G.; Pandey, R. K.; Racie, T.; Rajeev, K. G.; Roehl, I.; Toudjarska, I.; Wang, G.; Wuschko, S.; Bumcrot, D.; Koteliansky, V.; Limmer, S.; Manoharan, M.; Vornlocher, H.-P. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432, 173-178.
97. Bennett, C. F.; Swayze, E.; Geary, R.; Levin, A. A.; Mehta, R.; Teng, C.-L.; Tillman, L.; Hardee, G. Antisense oligonucleotide-based therapeutics. In Gene and Cell Therap, 2nd Ed.; Templeton, N. S.; Ed.; Marcel Dekker, Inc.: New York 2004; pp 347-374.
98. Shoji, Y.; Nakashima, H. Current status of delivery systems to improve target efficacy of oligonucleotides. Curr. Pharm. Des. 2004, 10, 785-796.
99. Kalota, A.; Shetzline, S. E.; Gewirtz, A. M. Progress in the development of nucleic acid therapeutics for cancer. Cancer Biol. Ther. 2004, 3, 4-12.
100. Fischer, P. M. The design of drug candidate molecules as selective inhibitors of therapeutically relevant kinases. Curr. Med. Chem. 2004, 11, 1563-1583.
101. Kraker, A. J.; Booher, R. N. New Targets in Cell Cycle Regulation. Ann. Rep. Med. Chem. 1999, 34, 247-256.
102. Buolamwini, J. K. Cell cycle molecular targets in novel anticancer drug discovery. Curr. Pharm. Des. 2000, 6, 379-392.
103. Stevenson, C. S.; Capper, E. A.; Roshak, A. K.; Marquez, B.; Eichman, C.; Jackson, J. R.; Mattern, M.; Gerwick, W. H.; Jacobs, R. S.; Marshall, L. A. The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore. J. Pharmacol. Exp. Ther. 2002, 303, 858-866.
104. Stevenson, C. S.; Capper, E. A.; Roshak, A. K.; Marquez, B.; Grace, K.; Gerwick, W. H.; Jacobs, R. S.; Marshall, L. A. Scytonemin - a marine natural product inhibitor of kinases key in hyperproliferative inflammatory diseases. Inflamm. Res. 2002, 51, 112-114.
105. Fischer, P. M.; Lane, D. P. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics. Curr. Med. Chem. 2000, 7, 1213-1245.
106. Bain, J.; McLauchlan, H.; Elliott, M.; Cohen, P. The specificities of protein kinase inhibitors: an update. Biochem. J. 2003, 371, 199-204.
107. Davies, S. P.; Reddy, H.; Caivano, M.; Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 2000, 351, 95-105.
108. Walker, E. H.; Pacold, M. E.; Perisic, O.; Stephens, L.; Hawkins, P. T.; Wymann, M. P.; Williams, R. L. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell 2000, 6, 909-919.
109. Greer, J. Comparative modeling methods: application to the family of the mammalian serine proteases. Proteins 1990, 7 317-334.
110. Pearson, W. R. Flexible sequence similarity searching with the FASTA3 program package. Methods Mol. Biol. 2000, 132 185-219.
111. Taylor, S. S.; Radzio-Andzelm, E.; Madhusudan; Cheng, X.; Ten Eyck, L.; Narayana, N. Catalytic subunit of cyclic AMP-dependent protein kinase: structure and dynamics of the active site cleft. Pharmacol. Ther. 1999, 82, 133-141.
112. Sausville, E. A. Aurora kinases dawn as cancer drug targets. Nat. Med. 2004, 10, 234-235.
113. Kandel, E. S.; Hay, N. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp. Cell Res. 1999, 253, 210-229.
114. Wymann, M. P.; Pirola, L. Structure and function of phosphoinositide 3-kinases. Biochim. Biophys. Acta 1998, 8 1-2.
115. Venkatachalam, C. M.; Ramachandran, G. N. Conformation of polypeptide chains. Ann. Rev. Biochem. 1973, 38, 45-77.
116. Singh, J.; Dobrusin, E. M.; Fry, D. W.; Haske, T.; Whitty, A.; McNamara, D. J. Structure-Based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases. J. Med. Chem. 1997, 40, 1130-1135.
117. Gray, N. S.; Wodicka, L.; Thunissen, A.-M. W. H.; Norman, T. C.; Kwon, S.; Espinoza, F. H.; Morgan, D. O.; Barnes, G.; LeClerc, S.; Meijer, L.; Kim, S.-H.; Lockhart, D. J.; Schultz, P. G. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 1998, 281, 533-538.
118. Agullo, G.; Gamet-Payrastre, L.; Manenti, S.; Viala, C.; Remesy, C.; Chap, H.; Payrastre, B. Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition. Biochem. Pharmacol. 1997, 53, 1649-1657.
119. Gamet-Payrastre, L.; Manenti, S.; Gratacap, M.-P.; Tulliez, J.; Chap, H.; Payrastre, B. Flavonoids and the inhibition of PKC and PI 3-kinase. Gen. Pharmacol. 1999, 32, 279-286.
120. Vlahos, C. J.; Matter, W. F.; Hui, K. Y.; Brown, R. F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 1994, 269, 5241-5248.
121. Wang, S.; Wood, G.; Meades, C.; Griffiths, G.; Midgley, C.; McNae, I.; McInnes, C.; Anderson, S.; Jackson, W.; Mezna, M.; Yuill, R.; Walkinshaw, M.; Fischer, P. M. Synthesis and biological activity of 2-Anilino-4-(1H-pyrrol-3-yl)pyrimidine CDK inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 4237-4240.
122. Wang, S.; Meades, C.; Wood, G.; Osnowski, A.; Anderson, S.; Yuill, R.; Thomas, M.; Mezna, M.; Jackson, W.; Midgley, C.; Griffiths, G.; Fleming, I.; Green, S.; McNae, I.; Wu, S.-Y.; McInnes, C.; Zheleva, D.; Walkinshaw, M. D.; Fischer, P. M. 2-Anilino-4-(thiazol-5-yl) pyrimidine CDK Inhibitors: Synthesis, SAR analysis, X-Ray Crystallography, and Biological Activity. J. Med. Chem. 2004, 47, 1662-1675.
123. Wu, S. Y.; McNae, I.; Kontopidis, G.; McClue, S. J.; McInnes, C.; Stewart, K. J.; Wang, S.; Zheleva, D. I.; Marriage, H.; Lane, D. P.; Taylor, P.; Fischer, P. M.; Walkinshaw, M. D. Discovery of a Novel Family of CDK Inhibitors with the Program LIDAEUS: Structural Basis for Ligand-Induced Disordering of the Activation Loop. Structure 2003, 11, 399-410.
124. McInnes, C.; Mezna, M.; Griffiths, G.; Grabek, J.; Midgely, C.; O'Boyle, J.; Green, S.; Meades, C.; Osknowski, A.; Melville, J.; Plater, A.; Pandit, N.; Taylor, P.; Zheleva, D.; Wang, S.; Jackson, R.; Glover, D.; Lane, D.; Walkinshaw, M.; M.Fischer, P. Structure-based ligand discovery and anti-tumor effects of polo-like kinase-1 ATP-competitive inhibitors. Clin. Cancer Res. 2003, 9 (16; Suppl.), Abs. A191.
125. McInnes, C.; Meades, C.; Mezna, M.; Fischer, P. Benzthiazole-3 oxides useful for the treatment of proliferative disorders. PCT Int. Pat. Appl. Publ. WO 2004067000; Cyclacel Limited, UK.
126. Umehara, H.; Yamashita, Y.; Tsujita, T.; Arai, H.; Hagihara, K.; Machii, D. Preparation of 2-aminopyrimidine derivatives as polo-like kinase inhibitors for treatment of tumor. PCT Int. Pat. Appl. Publ. WO 2004043936; Kyowa Hakko Kogyo Co., Ltd., Japan.
127. Davis-Ward, R.; Mook, R. A. Jr.; Neeb, M. J.; Salovich, J. M. Preparation of pyrimidine derivatives as Polo-like kinases inhibitors for treatment of cancers. PCT Int. Pat. Appl. Publ. WO 2004074244; SmithKline Beecham Corporation, USA.
128. Andrews, C. W., III; Cheung, M.; Davis-Ward, R. G.; Drewry, D. H.; Emmitte, K. A.; Hubbard, R. D.; Kuntz, K. W.; Linn, J. A.; Mook, R. A.; Smith, G. K.; Veal, J. M. Preparation of benzimidazolyl substituted thiophenes as Polo like kinases (PLK) inhibitors for treating cancer. PCT Int. Pat. Appl. Publ. WO 2004014899; SmithKline Beecham Corporation, USA.
129. Reddy, P. E.; Reddy, R. M. V.; Bell, S. C. Preparation of amino-substituted 1(E)-2,6-diakoxystyryl 4-substituted benzyl sulfones for treating proliferative disorders. PCT Int. Pat. Appl. Publ. WO 2003072062; Temple University-of the Commonwealth System of Higher Education, USA; Onconova Therapeutics, Inc.
130. Masuda, Y.; Nishida, A.; Hori, K.; Hirabayashi, T.; Kajimoto, S.; Nakajo, S.; Kondo, T.; Asaka, M.; Nakaya, K. beta-Hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1). Oncogene 2003, 22, 1012-1023.
131. Tanaka, H.; Ohshima, N.; Ikenoya, M.; Komori, K.; Katoh, F.; Hidaka, H. HMN-176, an active metabolite of the synthetic antitumor agent HMN-214, restores chemosensitivity to multidrug-resistant cells by targeting the transcription factor NF-Y. Cancer Res. 2003, 63, 6942-6947.
132. Von Hoff, D. D.; Taylor, C.; Rubin, S.; Cohen, J.; Garland, L. A Phase I and pharmacokinetic study of HMN-214, a novel oral polo-like kinase inhibitor, in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 2004, Abs. 3034.
133. Lee, K. S.; Grenfell, T. Z.; Yarm, F. R.; Erikson, R. L. Mutation of the polo-box disrupts localization and mitotic functions of the mammalian polo kinase Plk. Proc. Natl. Acad. Sci. USA 1998 95, 9301-9306.
134. Lee, K. S.; Song, S.; Erikson, R. L. The polo-box-dependent induction of ectopic septal structures by a mammalian polo kinase, Plk, in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA 1999, 96, 14360-14365.
135. Seong, Y.-S.; Kamijo, K.; Lee, J.-S.; Fernandez, E.; Kuriyama, R.; Miki, T.; Lee, K. S. A spindle checkpoint arrest and a cytokinesis failure by the dominant-negative polo-box domain of Plk1 in U-2 OS cells. J. Biol. Chem. 2002, 277, 32282-32293.
136. Yuan, J.; Kramer, A.; Eckerdt, F.; Kaufmann, M.; Strebhardt, K. Efficient internalization of the polo-box of polo-like kinase 1 fused to an antennapedia peptide results in inhibition of cancer cell proliferation. Cancer Res. 2002, 62, 4186-4190.
137. May, K. M.; Reynolds, N.; Cullen, C. F.; Yanagida, M.; Ohkura, H. Polo boxes and Cut23 (Apc8) mediate an interaction between polo kinase and the anaphase-promoting complex for fission yeast mitosis. J. Cell. Biol. 2002, 156, 23-28.
138. Nakajima, H.; Toyoshima-Morimoto, F.; Taniguchi, E.; Nishida, E. Identification of a consensus motif for Plk (Polo-like kinase) phosphorylation reveals Myt1 as a Plk1 substrate. J. Biol. Chem. 2003, 278, 25277-25280.
139. Neef, R.; Preisinger, C.; Sutcliffe, J.; Kopajtich, R.; Nigg, E. A.; Mayer, T. U.; Barr, F. A. Phosphorylation of mitotic kinesin-like protein 2 by polo-like kinase 1 is required for cytokinesis. J. Cell. Biol. 2003, 162, 863-875.
140. Elia, A. E. H.; Cantley, L. C.; Yaffe, M. B. Proteomic screen finds pSer/pthr-binding domain localizing Plk1 to mitotic substrates. Science 2003, 299, 1228-1231.
141. Westendorf, J. M.; Rao, P. N.; Gerace, L. Cloning of cDNAs for M-phase phosphoproteins recognized by the MPM2 monoclonal antibody and determination of the phosphorylated epitope. Proc. Natl. Acad. Sci. USA 1994, 91, 714-718.
142. Davis, F. M.; Tsao, T. Y.; Fowler, S. K.; Rao, P. N. Monoclonal antibodies to mitotic cells. Proc. Natl. Acad. Sci. USA 1983, 80, 2926-2930.
143. Yaffe, M. B.; Schutkowski, M.; Shen, M.; Zhou, X. Z.; Stukenberg, P. T.; Rahfeld, J. U.; Xu, J.; Kuang, J.; Kirschner, M. W.; Fischer, G.; Cantley, L. C.; Lu, K. P. Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. Science 1997, 278, 1957-1960.
144. Kumagai, A.; Dunphy, W. G. Regulation of the cdc25 protein during the cell cycle in Xenopus extracts. Cell 1992, 70 139-151.
145. Cheng, K.-Y.; Lowe, E. D.; Sinclair, J.; Nigg, E. A.; Johnson, L. N. The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex. EMBO J. 2003, 22, 5757-5768.
146. Elia, A. E. H.; Rellos, P.; Haire, L. F.; Chao, J. W.; Ivins, F. J.; Hoepker, K.; Mohammad, D.; Cantley, L. C.; Smerdon, S. J.; Yaffe, M. B. The Molecular Basis for Phosphodependent Substrate Targeting and Regulation of Plks by the Polo-Box Domain. Cell 2003, 115 83-95.
147. Leung, G. C.; Hudson, J. W.; Kozarova, A.; Davidson, A.; Dennis, J. W.; Sicheri, F. The Sak polo-box comprises a structural domain sufficient for mitotic subcellular localization. Nat. Struct. Biol. 2002, 9, 719-724.
148. Pawson, T.; Scott, J. D. Signaling through scaffold, anchoring, and adaptor proteins. Science 1997, 278, 2075-2080.
149. Sawyer, T. K.; Bohacek, R. S.; Dalgarno, D. C.; Eyermann, C. J.; Kawahata, N.; Metcalf, C. A., 3rd; Shakespeare, W. C.; Sundaramoorthi, R.; Wang, Y.; Yang, M. G. SRC homology-2 inhibitors: peptidomimetic and nonpeptide. Mini Rev. Med. Chem. 2002, 2, 475-488.
150. Smerdon, S. J,; Yaffe, M. B. Recognition of phosphoserine/ threonine phosphorylated proteins. In Handbook of Cell Signaling, Vol. 1; Bradshaw, R. A.; Dennis, E. A.; Eds.; 2004, Elsevier: San Diego, CA, 2004, pp 505-511.
151. Yaffe, M. B.; Rittinger, K.; Volinia, S.; Caron, P. R.; Aitken, A.; Leffers, H.; Gamblin, S. J.; Smerdon, S. J.; Cantley, L. C. The structural basis for 14-3-3:phosphopeptide binding specificity. Cell 1997, 91, 961-971.
152. Durocher, D.; Taylor, I. A.; Sarbassova, D.; Haire, L. F.; Westcott, S. L.; Jackson, S. P.; Smerdon, S. J.; Yaffe, M. B. The molecular basis of FHA domain:phosphopeptide binding specificity and implications for phospho-dependent signaling mechanisms. Mol. Cell 2000, 6, 1169-1182.
153. Altschul, S. F.; Madden, T. L.; Schaffer, A. A.; Zhang, J.; Zhang, Z.; Miller, W.; Lipman, D. J. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997, 25, 3389-3402
154. Hudson, J. W.; Kozarova, A.; Cheung, P.; Macmillan, J. C.; Swallow, C. J.; Cross, J. C.; Dennis, J. W. Late mitotic failure in mice lacking Sak, a polo-like kinase. Curr. Biol. 2001, 11, 441-446.
155. Thompson, J. D.; Higgins, D. G.; Gibson, T. J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994, 22, 4673-4680.
156. Rao, V. D.; Misra, S.; Boronenkov, I. V.; Anderson, R. A.; Hurley, J. H. Structure of type IIβ phosphatidylinositol phosphate kinase: a protein kinase fold flattened for interfacial phosphorylation. Cell 1998, 94, 829-839.
157. Lawrie, A. M.; Noble, M. E.; Tunnah, P.; Brown, N. R.; Johnson, L. N.; Endicott, J. A. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nat. Struct. Biol. 1997, 4, 796-801.
158. Zhao, B.; Bower, M. J.; McDevitt, P. J.; Zhao, H.; Davis, S. T.; Johanson, K. O.; Green, S. M.; Concha, N. O.; Zhou, B.-B. S. Structural Basis for Chk1 Inhibition by UCN-01. J. Biol. Chem. 2002, 277, 46609-46615.
159. Komander, D.; Kular, G. S.; Bain, J.; Elliott, M.; Alessi, D. R.; van Aalten, D. M. F. Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition. Biochem. J. 2003, 375, 255-262.
160. Bertrand, J. A.; Thieffine, S.; Vulpetti, A.; Cristiani, C.;
161. Prade, L.; Engh, R. A.; Girod, A.; Kinzel, V.; Huber, R.; Bossemeyer, D. Staurosporine-induced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential. Structure 1997, 5, 1627-1637.